Zobrazeno 1 - 10
of 496
pro vyhledávání: '"Lishan, Kang"'
Autor:
Hiroyasu Konno, Tracey Lin, Renyi Wu, Xinchuan Dai, Shou Li, Grace Wang, Min Chen, Wenying Li, Lina Wang, Bee-Chun Sun, Zhen Luo, Tom Huang, Yuping Chen, John Zhang, Qiuping Ye, David Bellovin, Bing Wan, Lishan Kang, Christopher Szeto, Karl Hsu, Omar Kabbarah
Publikováno v:
Cancer Research Communications. 2:937-950
CLDN18.2 (Claudin18.2)-targeting therapeutic antibodies have shown promising clinical efficacy in approximately 30% of gastric cancers expressing high levels of CLDN18.2 and less pronounced activity in low expressing malignancies. Here, we report tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40e38579a83e8994cc7832763313ddf6
https://doi.org/10.1158/2767-9764.crc-22-0216
https://doi.org/10.1158/2767-9764.crc-22-0216
Autor:
Omar Kabbarah, Karl Hsu, Christopher Szeto, Lishan Kang, Bing Wan, David Bellovin, Qiuping Ye, John Zhang, Yuping Chen, Tom Huang, Zhen Luo, Bee-Chun Sun, Lina Wang, Wenying Li, Min Chen, Grace Wang, Shou Li, Xinchuan Dai, Renyi Wu, Tracey Lin, Hiroyasu Konno
Supplementary Figure 5 shows IHC for gastric PDX models with anti-CLDN18.2, human IgG, or NKp46 antibody.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1646c177c59c326d2fda4eeccae51faf
https://doi.org/10.1158/2767-9764.22545570.v1
https://doi.org/10.1158/2767-9764.22545570.v1
Autor:
Omar Kabbarah, Karl Hsu, Christopher Szeto, Lishan Kang, Bing Wan, David Bellovin, Qiuping Ye, John Zhang, Yuping Chen, Tom Huang, Zhen Luo, Bee-Chun Sun, Lina Wang, Wenying Li, Min Chen, Grace Wang, Shou Li, Xinchuan Dai, Renyi Wu, Tracey Lin, Hiroyasu Konno
CLDN18.2 (Claudin18.2)-targeting therapeutic antibodies have shown promising clinical efficacy in approximately 30% of gastric cancers expressing high levels of CLDN18.2 and less pronounced activity in low expressing malignancies. Here, we report tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23593d81e787887277aaaf7ae7488821
https://doi.org/10.1158/2767-9764.c.6550980
https://doi.org/10.1158/2767-9764.c.6550980
Autor:
Jing Zhang, Wenhua Shi, Min Chen, Xinchuan Dai, Hongshui Liu, Shou Li, Lina Wang, Bee-Chun Sun, Monica You, Vivian Morton, Qiuping Ye, Lishan Kang, Bing Wan, Peter Brams, David I. Bellovin
Publikováno v:
Cancer Research. 82:3590-3590
Despite the promise of immunotherapy for cancer treatment, nearly 80% of patients fail to respond to checkpoint inhibitor (CPI) therapy. Regulatory T cells (Tregs), which inhibit immune responses in the tumor microenvironment via multiple suppressive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a765a1cb55f1e9c9fff451096351b7a8
https://doi.org/10.1158/1538-7445.am2022-3590
https://doi.org/10.1158/1538-7445.am2022-3590
Autor:
Bing Wan, Lishan Kang, Hiroyasu Konno, Bee Sun, David I. Bellovin, Wenhua Shi, Min Chen, Petter Veiby, Li Shou, Xinchuan Dai, James Yan, Lishen Shan, Karl Hsu, Bingbing Wang, Sophia Yin, Wenying Li, Holly Li, Yong Li, Omar Kabbarah, Frank Tao
Publikováno v:
Cancer Research. 81:1203-1203
Targeting the lineage marker CLDN18.2 with ADCC-eliciting monoclonal antibody therapeutics has shown promising clinical activity in the gastric, esophageal, and pancreatic cancer indications. However, clinical efficacy was mainly observed in tumors t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19abbf528dbc26a6515a4f37890474a8
https://doi.org/10.1158/1538-7445.am2021-1203
https://doi.org/10.1158/1538-7445.am2021-1203
Autor:
Bing Wan, Lin Yuan, Lei Wang, David I. Bellovin, Petter Veiby, Li Shou, Yusong Zhu, Frank Tao, Omar Kabbarah, Holly Li, Lishan Kang, James Yan, Xu Fang, Wenhua Shi, Karl Hsu, Haiying Zhou, Qi Shali, Sophia Yin
Publikováno v:
Cancer Research. 81:498-498
The interaction between CD47 that is overexpressed on tumor cells and SIRPα on macrophages facilitates a “don't-eat-me” signal that inhibits macrophage-mediated phagocytosis of tumor cells. Blockade of the CD47/SIRPα interaction using antibodie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cdb59da2b1a98f80e4b9a58b9a0ab719
https://doi.org/10.1158/1538-7445.am2021-498
https://doi.org/10.1158/1538-7445.am2021-498
Autor:
Zhishuang Guan, Jinjing Xu, Dongxia Hao, Henrik Østergaard, Wei Yang, Lin Wang, Zhuoxiao Cao, Chih-Chuan Chang, Hong Cheng, Zibing Liu, Haibin Chen, Liu Wei, Chenxi Shen, Bing Shan, Fengting Xu, Di Liu, Bingke Yu, Wan Wang, Lujia Peng, Xun Li, Haisun Zhu, Jishu Wang, Haimei Xing, Zhiru Yang, Li Yang, Lin Li, Tengkun Li, Jing Su, Tzu-Yuan Chao, Zhe Sun, Yanping Du, Dapeng Li, Søren Berg Padkjær, Lishan Kang, Dennis Madsen, Esper Boel
Publikováno v:
Journal of Biotechnology. 260:18-30
Interactions between protein ligands and receptors play crucial roles in cell-cell signalling. Most of the human cell surface receptors have been identified in the post-Human Genome Project era but many of their corresponding ligands remain unknown.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f7b626364d5cbd96410e49c5fbee618
https://doi.org/10.1016/j.jbiotec.2017.08.023
https://doi.org/10.1016/j.jbiotec.2017.08.023
Autor:
Ying Wang, Lili Wang, Lishan Kang, Tianshu Xu, Tianlei Ying, Liang Cheng, Liping Wang, Tao Huang, Qi Zhao, Xiaohua Douglas Zhang
Publikováno v:
Oncotarget
Anti-tumor necrosis factor (TNF) therapies are successful in the treatment of inflammatory disorders. However, some patients with rheumatoid arthritis (RA) fail to response anti-TNF drugs due to the compensation of other inflammatory signals. In this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc10539236ea2ddd9e99ae3d6ae9f50f
http://europepmc.org/articles/PMC5669854
http://europepmc.org/articles/PMC5669854
Publikováno v:
Current Pharmaceutical Biotechnology. 17:1324-1332
Bispecific antibodies with binding specificities for two different antigens have prompted a lot of interest into their development and application. Currently, more than ten bispecific antibodies have been clinically validated for the treatment of var
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dee752af5c11478f1eceaf1f08f52c4a
https://doi.org/10.2174/1389201017666161018150553
https://doi.org/10.2174/1389201017666161018150553
Autor:
Yan Li1, Lishan Kang1 kang@whu.edu.cn, Zhuo Kang, V. S.1, Pu Liu1, De Garis, Hugo2 degaris@starlab.net
Publikováno v:
International Journal of Computer Mathematics. May2002, Vol. 79 Issue 5, p523-536. 14p. 1 Diagram, 3 Charts, 1 Graph.